Neuphoria Therapeutics (NEUP) Short-term Investments (2021 - 2025)
Neuphoria Therapeutics (NEUP) posted quarterly Short-term Investments of $79647.0 for Q4 2025, up 1.38% quarter-over-quarter from $78564.0 in Q3 2025.
Neuphoria Therapeutics (NEUP) Short-term Investments (2021 - 2025) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Short-term Investments for 2 consecutive years, with $79647.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Short-term Investments changed N/A year-over-year to $79647.0; the TTM figure through Dec 2025 stood at $79647.0 (changed N/A YoY), while the FY2025 annual figure was $77945.0, changed N/A from the prior year.
- Short-term Investments climbed to $79647.0 in Q4 2025 per NEUP's latest filing, from $78564.0 in the prior quarter.
- Across five years, Short-term Investments topped out at $335466.8 in Q2 2021 and bottomed at $77945.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Neuphoria Therapeutics | 21.28 Mn | 1.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 79,647.00 |
| Sep 30, 2025 | 78,564.00 |
| Jun 30, 2025 | 77,945.00 |
| Jun 30, 2021 | 335,466.82 |